Generic Name

Ezetimibe

Brand Names
Zetia, Nexlizet
FDA approval date: June 12, 2017
Classification: Adenosine Triphosphate-Citrate Lyase Inhibitor
Form: Tablet

What is Zetia (Ezetimibe)?

High cholesterol is a silent condition, it doesn’t cause pain or obvious symptoms, yet it significantly increases the risk of heart attack and stroke. For millions of people, managing cholesterol levels is an essential part of staying healthy and preventing serious cardiovascular problems. Zetia (ezetimibe) is a medication designed to help lower cholesterol, especially when diet, exercise, and other treatments alone are not enough. 

Zetia belongs to a class of drugs known as cholesterol absorption inhibitors. Unlike statins, which work by reducing cholesterol production in the liver, Zetia helps block cholesterol absorption in the small intestine. This complementary mechanism makes it useful both as a stand-alone treatment and in combination with statins for better cholesterol control. Since its approval by the U.S. Food and Drug Administration (FDA) in 2002, Zetia has become a well-established and widely used therapy in managing elevated cholesterol levels. 

What does Zetia do? 

Zetia is primarily prescribed to lower levels of “bad” cholesterol, known as low-density lipoprotein (LDL), in the blood. It may also help modestly reduce total cholesterol and triglycerides, while increasing “good” cholesterol (HDL). 

Doctors typically recommend Zetia for patients who: 

  • Have high cholesterol (hypercholesterolemia) not adequately controlled by diet and exercise alone.[Text Wrapping Break] 
  • Cannot tolerate statins due to side effects.[Text Wrapping Break] 
  • Need additional cholesterol lowering despite already taking a statin.[Text Wrapping Break] 
  • Have certain inherited cholesterol disorders, such as familial hypercholesterolemia. 

By reducing LDL levels, Zetia helps slow the buildup of fatty deposits in arteries (atherosclerosis), lowering the risk of heart disease and stroke. Clinical studies have shown that adding ezetimibe to a statin regimen can provide an additional 15–25% reduction in LDL cholesterol, improving overall cardiovascular outcomes (NIH, 2024). 

Patients who take Zetia as part of a broader lifestyle plan including a heart-healthy diet, regular exercise, and avoiding smoking often report improved cholesterol numbers within a few weeks. 

How does Zetia work? 

Zetia works in a unique way compared to most cholesterol-lowering medications. It targets cholesterol absorption in the small intestine, preventing it from entering the bloodstream. Specifically, ezetimibe blocks a protein called NPC1L1 (Niemann-Pick C1-Like 1) located on the intestinal wall. 

This protein normally helps the body absorb cholesterol from the foods we eat and from bile produced by the liver. By blocking this process, Zetia reduces the total amount of cholesterol delivered to the liver. In response, the liver pulls more cholesterol from the bloodstream, leading to lower LDL levels overall. 

This mechanism is clinically important because it complements the action of statins, which reduce cholesterol production inside the liver. When used together, they offer a dual approach, less cholesterol absorbed from food and less produced by the body resulting in more effective cholesterol management with fewer side effects than increasing the statin dose alone. 

In simple terms, Zetia helps “turn down the faucet” of cholesterol coming from the diet, while statins “reduce the production” happening inside the body. 

Zetia side effects 

Zetia is generally well-tolerated, and most people experience little to no discomfort while taking it. However, as with all medications, side effects are possible. 

Common side effects include: 

  • Muscle or joint pain[Text Wrapping Break] 
  • Fatigue or weakness[Text Wrapping Break] 
  • Stomach pain, diarrhea, or gas[Text Wrapping Break] 
  • Headache 

Less common but potentially serious side effects may include: 

  • Unexplained muscle pain or tenderness (especially when taken with statins, as it may signal muscle injury)[Text Wrapping Break] 
  • Severe allergic reactions, including rash, swelling, or difficulty breathing[Text Wrapping Break] 
  • Liver enzyme elevations, which may indicate liver irritation 

Patients with moderate to severe liver disease should use Zetia cautiously and under close supervision. Those who have had allergic reactions to ezetimibe or any component of the drug should avoid it. 

Seek immediate medical attention if you develop unusual muscle pain, yellowing of the skin or eyes, dark urine, or swelling of the face and throat, as these may indicate rare but serious complications. 

Fortunately, the vast majority of patients tolerate Zetia well, particularly when used alone. Its favorable safety profile makes it a useful option for people who cannot handle higher doses of statins. 

Zetia dosage 

Zetia is an oral tablet taken once daily, with or without food. It can be prescribed alone or with a statin for enhanced cholesterol lowering. Patients should maintain a low-cholesterol, heart-healthy diet while taking it. 

Regular blood tests, including cholesterol and liver function, may be ordered, especially if Zetia is combined with a statin. Close monitoring is needed for older adults and those with liver impairment. Missed doses should be taken when remembered, unless it’s near the next dose. 

Does Zetia have a generic version? 

Yes. Ezetimibe is the generic form of Zetia, and it is FDA-approved for the same uses. Generic ezetimibe contains the same active ingredient, strength, dosage form, and safety profile as the brand-name version. 

Generic ezetimibe is now the standard, offering the same effectiveness as Zetia at a lower cost. Combination pills like ezetimibe with simvastatin (Vytorin) are also available. 

Conclusion 

Zetia (ezetimibe) is an effective, well-tolerated medication that helps lower cholesterol by blocking its absorption in the intestines. It can be used alone or alongside statins to achieve better cholesterol control and reduce the risk of heart disease. 

Alongside a healthy lifestyle, Zetia aids in long-term cardiovascular protection for those struggling with cholesterol goals through diet and exercise alone. Ongoing communication with your healthcare provider, regular checkups, lab monitoring, and adherence ensure safe and effective results. Consistent use and proper guidance empower patients towards a healthier heart and a longer, more active life. 

References 

  1. Mayo Clinic. (2024). Ezetimibe (oral route) description and precautions. Retrieved from https://www.mayoclinic.org[Text Wrapping Break] 
  1. MedlinePlus. (2024). Ezetimibe: Drug information. National Library of Medicine. Retrieved from https://medlineplus.gov[Text Wrapping Break] 
  1. National Institutes of Health (NIH). (2024). Cholesterol management and ezetimibe use overview. Retrieved from https://www.nih.gov[Text Wrapping Break] 
  1. U.S. Food and Drug Administration (FDA). (2023). Approved Drug Products: Ezetimibe (Zetia). Retrieved from https://www.accessdata.fda.gov 

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study

Summary: Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.

A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan - The CLEAR Taiwan Study

Summary: Cardiovascular disease (CVD) is a chronic non-communicable disease among the most common causes of death worldwide. Substantial reductions in risks of CVD can be achieved through the management of modifiable risk factors, particularly low-density lipoprotein cholesterol (LDL-C). However, only 18.3% of high-risk primary prevention patients and 20.7% of secondary prevention patients achieved the tre...

Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE Stabilization

Summary: This study is a prospective, multicenter, randomized clinical trial aimed at comparing the effects of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy on coronary plaque stabilization. Using advanced imaging techniques such as near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), the trial evaluates whether the combination therapy is ...

Brand Information

    Zetia (Ezetimibe)
    1INDICATIONS AND USAGE
    ZETIA
    • In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).
    • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.
    • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.
    • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).
    • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.
    When ZETIA is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.
    2DOSAGE AND ADMINISTRATION
    • The recommended dose of ZETIA is 10 mg orally once daily, administered with or without food.
    • If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.
    • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ZETIA.
    • Administer ZETIA at least 2 hours before or 4 hours after administration of a bile acid sequestrant
    3DOSAGE FORMS AND STRENGTHS
    Tablets: 10-mg white to off-white, capsule-shaped, and debossed with "414" on one side.
    4CONTRAINDICATIONS
    ZETIA is contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ZETIA. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported
    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications
    5ADVERSE REACTIONS
    The following serious adverse reactions are discussed in greater detail in other sections of the label:
    • Liver enzyme abnormalities
    • Rhabdomyolysis and myopathy
    5.1Clinical Trials Experience
    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
    5.2Post-Marketing Experience
    Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
    The following additional adverse reactions have been identified during post-approval use of ZETIA:
    Blood Disorders: thrombocytopenia
    Gastrointestinal Disorders: abdominal pain; pancreatitis; nausea
    Hepatobiliary Disorders: elevations in liver transaminases, including elevations more than 5 X ULN; hepatitis; cholelithiasis; cholecystitis
    Immune System Disorders: Hypersensitivity reactions including: anaphylaxis, angioedema, rash, and urticaria
    Musculoskeletal Disorders: elevated creatine phosphokinase; myopathy/rhabdomyolysis
    Nervous System Disorders: dizziness; paresthesia; depression; headache
    Skin and Subcutaneous Tissue Disorders: erythema multiforme
    6DRUG INTERACTIONS
    Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZETIA and instructions for preventing or managing them.
    7OVERDOSAGE
    In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
    8DESCRIPTION
    ZETIA (ezetimibe) is a dietary cholesterol absorption inhibitor. The chemical name of ezetimibe is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C
    Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is stable at ambient temperature. ZETIA is available as a tablet for oral use containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone USP, and sodium lauryl sulfate NF.
    9CLINICAL STUDIES
    Primary Hyperlipidemia in Adults
    ZETIA reduces total-C, LDL-C, Apo B, and non-HDL-C in patients with hyperlipidemia. Maximal to near maximal response is generally achieved within 2 weeks and maintained during chronic therapy.
    Monotherapy
    In two multicenter, double-blind, placebo-controlled, 12-week trials in 1719 patients (age range 18 to 86 years, 52% females; 91% White, 5% Black or African American, 1% Asian, 3% other races mostly identified as Hispanic or Latino ethnicity) with primary hyperlipidemia, ZETIA significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to placebo (see
    Combination with Statins: ZETIA Added to On-going Statin Therapy
    In a multicenter, double-blind, placebo-controlled, 8-week trial, 769 patients (age range 22 to 85 years, 42% females; 90% White, 6% Black or African American, 1% Asian, 3% other races; and 2% identified as Hispanic or Latino ethnicity) with primary hyperlipidemia, known coronary heart disease or multiple cardiovascular risk factors who were already receiving statin monotherapy but who had not met their NCEP ATP II target LDL-C goal, were randomized to receive either ZETIA or placebo in addition to their on-going statin.
    ZETIA, added to on-going statin therapy, significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared with a statin administered alone (see
    Combination with Statins: ZETIA Initiated Concurrently with a Statin
    In four multicenter, double-blind, placebo-controlled, 12-week trials, in 2,382 patients (age range 18 to 87 years, 57% female; 88% White, 5% Black or African American, 2% Asian, 5% other races mostly identified as Hispanic or Latino) with hyperlipidemia, ZETIA or placebo was administered alone or with various doses of atorvastatin, simvastatin, pravastatin, or lovastatin.
    When all patients receiving ZETIA with a statin were compared to all those receiving the corresponding statin alone, ZETIA significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to the statin administered alone. LDL-C reductions induced by ZETIA were generally consistent across all statins. (See footnote
    Combination with Fenofibrate
    In a multicenter, double-blind, placebo-controlled, clinical trial in patients with mixed hyperlipidemia, 625 patients (age range 20 to 76 years, 44% female; 79% White, 1% Black or African American, 20% other races; and 11% identified as Hispanic or Latino ethnicity) were treated for up to 12 weeks and 576 for up to an additional 48 weeks. Patients were randomized to receive placebo, ZETIA alone, 160 mg fenofibrate alone, or ZETIA and 160 mg fenofibrate in the 12-week trial. After completing the 12-week trial, eligible patients were assigned to ZETIA coadministered with fenofibrate or fenofibrate monotherapy for an additional 48 weeks.
    ZETIA coadministered with fenofibrate significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to fenofibrate administered alone (see
    The changes in lipid endpoints after an additional 48 weeks of treatment with ZETIA coadministered with fenofibrate or with fenofibrate alone were consistent with the 12-week data displayed above.
    HeFH in Pediatric Patients
    The effects of ZETIA coadministered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in males and females with HeFH. In a multicenter, double-blind, controlled trial followed by an open-label phase, 142 males and 106 postmenarchal females, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% White, 4% Asian, 2% Black or African American, 13% multi-racial; 14% identified as Hispanic or Latino ethnicity) with HeFH were randomized to receive either ZETIA coadministered with simvastatin or simvastatin monotherapy. Inclusion in the trial required 1) a baseline LDL-C level between 160 and 400 mg/dL and 2) a medical history and clinical presentation consistent with HeFH. The mean baseline LDL-C value was 225 mg/dL (range: 161 to 351 mg/dL) in the ZETIA coadministered with simvastatin group compared to 219 mg/dL (range: 149 to 336 mg/dL) in the simvastatin monotherapy group. The patients received coadministered ZETIA and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ZETIA and 40-mg simvastatin or 40-mg simvastatin monotherapy for the next 27 weeks, and open-label coadministered ZETIA and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.
    The results of the trial at Week 6 are summarized in
    HoFH in Adults and Pediatric Patients
    A trial was conducted to assess the efficacy of ZETIA in the treatment of HoFH. This double-blind, randomized, 12-week trial enrolled 50 patients (age range 11 to 74 years, 58% female; 90% White, 2% Black or African American, 8% other races identified as Hispanic or Latino) with a clinical and/or genotypic diagnosis of HoFH, with or without concomitant LDL apheresis, already receiving atorvastatin or simvastatin (40 mg). Patients were randomized to one of three treatment groups, atorvastatin or simvastatin (80 mg), ZETIA administered with atorvastatin or simvastatin (40 mg), or ZETIA administered with atorvastatin or simvastatin (80 mg). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine
    Homozygous Sitosterolemia (Phytosterolemia) in Adults and Pediatric Patients
    A trial was conducted to assess the efficacy of ZETIA in the treatment of homozygous sitosterolemia. In this multicenter, double-blind, placebo-controlled, 8-week trial, 37 patients (age range 9 to 72 years, 65% females; 89% White, 3% Asian, 8% other races identified as Hispanic or Latino) with homozygous sitosterolemia with elevated plasma sitosterol levels (>5 mg/dL) on their current therapeutic regimen (diet, bile-acid-binding resins, statins, ileal bypass surgery and/or LDL apheresis), were randomized to receive ZETIA (n=30) or placebo (n=7). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine
    10HOW SUPPLIED/STORAGE AND HANDLING
    ZETIA 10 mg tablets are white to off-white, capsule-shaped, and debossed with "414" on one side and are supplied as follows:
    11PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-Approved Patient Labeling (
    Inform patients that ZETIA may cause liver enzyme elevations
    Muscle Pain
    Advise patients that ZETIA may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever
    Pregnancy
    Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if ZETIA should be discontinued
    Breastfeeding
    Advise patients who have a lipid disorder and are breastfeeding to discuss the options with their healthcare provider
    Missed Dose
    Instruct patients to take ZETIA only as prescribed. If a dose is missed, it should be taken as soon as possible. Advise patients not to double their next dose.
    12PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
    NDC 78206-178-01
    Zetia
    10 mg
    Each tablet contains 10 mg ezetimibe.
    Rx only
    30 Tablets
    PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
    Zetia has been selected.